Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met-overexpressing (OE) advanced non-small cell lung cancer (NSCLC).

Basit Öğe Kaydı
dc.authoridMoiseenko, Fedor/0000-0003-2544-9042
dc.authoridBar, Jair/0000-0002-1224-3646;
dc.authorwosidMoiseenko, Fedor/E-1775-2014
dc.authorwosidBar, Jair/AAS-5743-2021
dc.authorwosidGirard, Nicolas/IAO-8135-2023
dc.authorwosidLu, Shun/ABF-8341-2021
dc.contributor.authorCamidge, D. Ross
dc.contributor.authorBar, Jair
dc.contributor.authorHorinouchi, Hidehito
dc.contributor.authorGoldman, Jonathan W.
dc.contributor.authorMoiseenko, Fedor Vladimirovich
dc.contributor.authorFilippova, Elena
dc.contributor.authorCicin, Irfan
dc.date.accessioned2024-06-12T11:24:07Z
dc.date.available2024-06-12T11:24:07Z
dc.date.issued2022
dc.departmentTrakya Üniversitesien_US
dc.descriptionAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- JUN 03-07, 2022 -- ELECTR NETWORKen_US
dc.description.abstract[Abstract Not Available]en_US
dc.description.sponsorshipAmer Soc Clin Oncolen_US
dc.description.sponsorshipAbbVieen_US
dc.description.sponsorshipAbbVie.en_US
dc.identifier.issn0732-183X
dc.identifier.issn1527-7755
dc.identifier.issue16en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/26813
dc.identifier.volume40en_US
dc.identifier.wosWOS:000863680302206en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofJournal Of Clinical Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject[No Keywords]en_US
dc.titleTelisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met-overexpressing (OE) advanced non-small cell lung cancer (NSCLC).en_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu